ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET                      NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

Continue reading here:
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

Global News Feed Comments Off on NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208 | December 28th, 2023

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and Adrulipase

Read more:
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Global News Feed Comments Off on First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program | December 28th, 2023

MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.

Excerpt from:
Opthea to Receive US$35M Commitment and Additional US$50M Funding

Global News Feed Comments Off on Opthea to Receive US$35M Commitment and Additional US$50M Funding | December 28th, 2023

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.

Read more from the original source:
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Global News Feed Comments Off on Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference | December 28th, 2023

WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company’s existing trading symbol “AVTX”.

Original post:
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Global News Feed Comments Off on Avalo Therapeutics Announces 1-for-240 Reverse Stock Split | December 28th, 2023

SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).

See the article here:
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Global News Feed Comments Off on Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer | December 28th, 2023

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)

Read this article:
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or...

Global News Feed Comments Off on Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or… | December 28th, 2023

In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNF?, reductions in tissue TNF? mRNA and improvement in disease activity scores

View original post here:
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small...

Global News Feed Comments Off on Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small… | December 28th, 2023

NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients

Read the original post:
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

Global News Feed Comments Off on NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease | December 28th, 2023

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs

Read more:
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Global News Feed Comments Off on Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108 | December 28th, 2023

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -

Go here to see the original:
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo®...

Global News Feed Comments Off on SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo®… | December 28th, 2023

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.

Visit link:
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Global News Feed Comments Off on Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) | December 28th, 2023

IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.

The rest is here:
Nymox December 27 Message to Shareholders

Global News Feed Comments Off on Nymox December 27 Message to Shareholders | December 28th, 2023

BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $5.50 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.8 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.

See the article here:
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

Global News Feed Comments Off on First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced | December 28th, 2023

MONMOUTH JUNCTION, N.J., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Thursday, January 11th at 10:30 A.M. PST.

Read more:
Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Global News Feed Comments Off on Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference | December 28th, 2023

New record date expected to be January 11, 2024

Go here to see the original:
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th

Global News Feed Comments Off on Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th | December 28th, 2023

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Read more:
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Global News Feed Comments Off on Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference | December 28th, 2023

What is a bone marrow transplant?

Bone marrow transplant (BMT) is a special therapy for patients with certain cancers or other diseases. A bone marrow transplant involves taking cells that are normally found in the bone marrow (stem cells), filtering those cells, and giving them back either to the donor (patient) or to another person. The goal of BMT is to transfuse healthy bone marrow cells into a person after his or her own unhealthy bone marrow has been treated to kill the abnormal cells.

Bone marrow transplant has been used successfully to treat diseases such as leukemias, lymphomas, aplastic anemia, immune deficiency disorders, and some solid tumor cancers since 1968.

Bone marrow is the soft, spongy tissue found inside bones. It is where most of the body's blood cells develop and are stored.

The blood cells that make other blood cells are called stem cells. The most primitive of the stem cells is called the pluripotent stem cell. This is different than other blood cells with regard to the following properties:

It is the stem cells that are needed in bone marrow transplant.

The goal of a bone marrow transplant is to cure many diseases and types of cancer. When the doses of chemotherapy or radiation needed to cure a cancer are so high that a person's bone marrow stem cells will be permanently damaged or destroyed by the treatment, a bone marrow transplant may be needed. Bone marrow transplants may also be needed if the bone marrow has been destroyed by a disease.

A bone marrow transplant can be used to:

Replace diseased, nonfunctioning bone marrow with healthy functioning bone marrow (for conditions such as leukemia, aplastic anemia, and sickle cell anemia).

Regenerate a new immune system that will fight existing or residual leukemia or other cancers not killed by the chemotherapy or radiation used in the transplant.

Replace the bone marrow and restore its normal function after high doses of chemotherapy and/or radiation are given to treat a malignancy. This process is often called rescue.

Replace bone marrow with genetically healthy functioning bone marrow to prevent more damage from a genetic disease process (such as Hurler's syndrome and adrenoleukodystrophy).

The risks and benefits must be weighed in a thorough discussion with your healthcare provider and specialists in bone marrow transplants before the procedure.

The following diseases are the ones that most commonly benefit from bone marrow transplant:

However, patients experience diseases differently, and bone marrow transplant may not be right for everyone who suffers from these diseases.

There are different types of bone marrow transplants depending on who the donor is. The different types of BMT include the following:

Autologous bone marrow transplant. The donor is the patient himself or herself. Stem cells are taken from the patient either by bone marrow harvest or apheresis (a process of collecting peripheral blood stem cells), frozen, and then given back to the patient after intensive treatment. Often the term rescue is used instead of transplant.

Allogeneic bone marrow transplant. The donor shares the same genetic type as the patient. Stem cells are taken either by bone marrow harvest or apheresis from a genetically matched donor, usually a brother or sister. Other donors for allogeneic bone marrow transplants may include the following:

A parent. A haploid-identical match is when the donor is a parent and the genetic match is at least half identical to the recipient. These transplants are rare.

Unrelated bone marrow transplants (UBMT or MUD for matched unrelated donor). The genetically matched marrow or stem cells are from an unrelated donor. Unrelated donors are found through national bone marrow registries.

Umbilical cord blood transplant. Stem cells are taken from an umbilical cord immediately after delivery of an infant. These stem cells reproduce into mature, functioning blood cells quicker and more effectively than do stem cells taken from the bone marrow of another child or adult. The stem cells are tested, typed, counted, and frozen until they are needed for a transplant.

Matching involves typing human leukocyte antigen (HLA) tissue. The antigens on the surface of these special white blood cells determine the genetic makeup of a person's immune system. There are at least 100 HLA antigens; however, it is believed that there are a few major antigens that determine whether a donor and recipient match. The others are considered "minor" and their effect on a successful transplant is not as well-defined.

Medical research is still investigating the role all antigens play in the process of a bone marrow transplant. The more antigens that match, the better the engraftment of donated marrow. Engraftment of the stem cells happens when the donated cells make their way to the marrow and begin making new blood cells.

Most of the genes that "code" for the human immune system are on one chromosome. Since we only have two of each chromosome, one we received from each of our parents, a full sibling of a patient in need of a transplant has a 1 in 4 chance of having gotten the same set of chromosomes and being a "full match" for transplantation.

The group of specialists involved in the care of patients going through transplant is often referred to as the transplant team. All individuals work together to give the best chance for a successful transplant. The team consists of the following:

Healthcare providers. Healthcare providers who specialize in oncology, hematology, immunology, and bone marrow transplantation.

Bone marrow transplant nurse coordinator. A nurse who organizes all aspects of care provided before and after the transplant. The nurse coordinator will provide patient education, and coordinates the diagnostic testing and follow-up care.

Social workers. Professionals who will help your family deal with many issues that may arise, including lodging and transportation, finances, and legal issues.

Dietitians. Professionals who will help you meet your nutritional needs before and after the transplant. They will work closely with you and your family.

Physical therapists. Professionals who will help you become strong and independent with movement and endurance after the transplantation.

Pastoral care. Chaplains who provide spiritual care and support.

Other team members. Several other team members will evaluate you before transplantation and will give follow-up care as needed. These include, but are not limited to, the following:

An extensive evaluation is completed by the bone marrow transplant team. The decision for you to undergo a bone marrow transplant will be based on many factors, including the following:

Your age, overall health, and medical history

Extent of the disease

Availability of a donor

Your tolerance for specific medicines, procedures, or therapies

Expectations for the course of the disease

Expectations for the course of the transplant

Your opinion or preference

For a patient receiving the transplant, the following will occur in advance of the procedure:

Before the transplant, an extensive evaluation is completed by the bone marrow transplant team. All other treatment choices are discussed and evaluated for risk versus benefit.

A complete medical history and physical exam are performed, including multiple tests to evaluate the patient's blood and organ functions (for example, heart, kidney, liver, and lungs).

A patient will often come into the transplant center up to 10 days before transplant for hydration, evaluation, placement of the central venous line, and other preparations. A catheter, also called a central venous line, is surgically placed in a vein in the chest area. Blood products and medicines will be given through the catheter during treatment.

For an allogeneic transplant, a suitable (tissue typed and matched) donor must be available. Finding a matching donor can be a challenging and lengthy process, especially if a sibling match is not available. Voluntary marrow donors are registered in several national and international registries. A bone marrow search involves searching these registries for donors whose blood most closely resembles or matches the individual needing the transplant.

Donor sources available include: self, sibling, parent or relative, nonrelated person, or umbilical cord from a related or nonrelated person. There are national and international registries for nonrelated people and cord blood. Some family members may be typed because of the desire to help. These relatives may or may not elect to have their type registered for use with other recipients.

If the potential donor is notified that he or she may be a match for a patient needing a transplant, he or she will undergo additional tests. Tests related to his or her health, exposure to viruses, and genetic analysis will be done to determine the extent of the match. The donor will be given instructions on how a bone marrow donation will be made.

Once a match for a patient needing a bone marrow transplant is found, then stem cells will be collected either by a bone marrow harvest. This is a collection of stem cells with a needle placed into the soft center of the bone marrow. Or by a peripheral blood stem cell collection. This is where stem cells are collected from the circulating cells in the blood. Of the two, peripheral blood stem cell donations are now more common. Cord blood has already been collected at the time of a birth and stored for later use.

A bone marrow transplant is done by transferring stem cells from one person to another. Stem cells can either be collected from the circulating cells in the blood (the peripheral system) or from the bone marrow.

Peripheral blood stem cells. Peripheral blood stem cells (PBSCs) are collected by apheresis. This is a process in which the donor is connected to a special cell separation machine via a needle inserted in arm veins. Blood is taken from one vein and is circulated though the machine which removes the stem cells and returns the remaining blood and plasma back to the donor through another needle inserted into the opposite arm. Several sessions may be needed to collect enough stem cells to ensure a chance of successful engraftment in the recipient.

A medicine may be given to the donor for about one week prior to apheresis that will stimulate the bone marrow to increase production of new stem cells. These new stem cells will be released from the marrow and into the circulating or peripheral blood system; from there they can be collected during apheresis.

Bone marrow harvest. Bone marrow harvesting involves collecting stem cells with a needle placed into the soft center of the bone, the marrow. Most sites used for bone marrow harvesting are located in the hip bones and the sternum. The procedure takes place in the operating room. The donor will be anesthetized during the harvest and will not feel the needle. In recovery, the donor may experience some pain in the areas where the needle was inserted.

If the donor is the person himself or herself, it is called an autologous bone marrow transplant. If an autologous transplant is planned, previously collected stem cells, from either peripheral (apheresis) or harvest, are counted, screened, and ready to infuse.

The preparations for a bone marrow transplant vary depending on the type of transplant, the disease needing transplant, and your tolerance for certain medicines. Consider the following:

Most often, high doses of chemotherapy and/or radiation are included in the preparations. This intense therapy is required to effectively treat the malignancy and make room in the bone marrow for the new cells to grow. This therapy is often called ablative, or myeloablative, because of the effect on the bone marrow. The bone marrow produces most of the blood cells in our body. Ablative therapy prevents this process of cell production and the marrow becomes empty. An empty marrow is needed to make room for the new stem cells to grow and establish a new blood cell production system.

After the chemotherapy and/or radiation is administered, the marrow transplant is given through the central venous catheter into the bloodstream. It is not a surgical procedure to place the marrow into the bone, but is similar to receiving a blood transfusion. The stem cells find their way into the bone marrow and begin reproducing and growing new, healthy blood cells.

After the transplant, supportive care is given to prevent and treat infections, side effects of treatments, and complications. This includes frequent blood tests, close monitoring of vital signs, strict measurement of fluid input and output, daily weigh-ins, and providing a protected and clean environment.

The days before transplant are counted as minus days. The day of transplant is considered day zero. Engraftment and recovery following the transplant are counted as plus days. For example, a patient may enter the hospital on day -8 for preparative regimen. The day of transplant is numbered zero. Days +1, +2, etc., will follow. There are specific events, complications, and risks associated with each day before, during, and after transplant. The days are numbered to help the patient and family understand where they are in terms of risks and discharge planning.

During infusion of bone marrow, the patient may experience the following:

Pain

Chills

Fever

Hives

Chest pain

After infusion, the patient may:

Spend several weeks in the hospital

Be very susceptible to infection

Experience excessive bleeding

Need blood transfusions

Be confined to a clean environment

Take multiple antibiotics and other medicines

Be given medicine to prevent graft-versus-host diseaseif the transplant was allogeneic. The transplanted new cells (the graft) tend to attack the patient's tissues (the host), even if the donor is a relative.

Undergo continual laboratory testing

Experience nausea, vomiting, diarrhea, mouth sores, and extreme weakness

Experience temporary mental confusion and emotional or psychological distress

After leaving the hospital, the recovery process continues for several months or longer, during which time the patient cannot return to work or many previously enjoyed activities. The patient must also make frequent follow-up visits to the hospital or healthcare provider's office.

Engraftment of the stem cells happens when the donated cells make their way to the marrow and begin making new blood cells. Depending on the type of transplant and the disease being treated, engraftment usually happens around day +15 or +30. Blood counts will be checked often during the days following transplant to evaluate initiation and progress of engraftment. Platelets are generally the last blood cell to recover.

Engraftment can be delayed because of infection, medicines, low donated stem cell count, or graft failure. Although the new bone marrow may begin making cells in the first 30 days following transplant, it may take months, even years, for the entire immune system to fully recover.

Complications may vary, depending on the following:

Type of marrow transplant

Type of disease requiring transplant

Preparative regimen

Age and overall health of the recipient

Variance of tissue matching between donor and recipient

Presence of severe complications

The following are complications that may happen with a bone marrow transplant. However, each individual may experience symptoms differently. These complications may also happen alone, or in combination:

Infections. Infections are likely in the patient with severe bone marrow suppression. Bacterial infections are the most common. Viral and fungal infections can be life-threatening. Any infection can cause an extended hospital stay, prevent or delay engraftment, and/or cause permanent organ damage. Antibiotics, antifungal medicines, and antiviral medicines are often given to try to prevent serious infection in the immunosuppressed patient.

Low platelets and low red blood cells. Thrombocytopenia (low platelets) and anemia (low red blood cells), as a result of a nonfunctioning bone marrow, can be dangerous and even life-threatening. Low platelets can cause dangerous bleeding in the lungs, gastrointestinal (GI) tract, and brain.

Pain. Pain related to mouth sores and gastrointestinal (GI) irritation is common. High doses of chemotherapy and radiation can cause severe mucositis (inflammation of the mouth and GI tract).

Fluid overload. Fluid overload is a complication that can lead to pneumonia, liver damage, and high blood pressure. The main reason for fluid overload is because the kidneys cannot keep up with the large amount of fluid being given in the form of intravenous (IV) medicines, nutrition, and blood products. The kidneys may also be damaged from disease, infection, chemotherapy, radiation, or antibiotics.

Respiratory distress. Respiratory status is an important function that may be compromised during transplant. Infection, inflammation of the airway, fluid overload, graft-versus-host disease, and bleeding are all potential life-threatening complications that may happen in the lungs and pulmonary system.

Organ damage. The liver and heart are important organs that may be damaged during the transplantation process. Temporary or permanent damage to the liver and heart may be caused by infection, graft-versus-host disease, high doses of chemotherapy and radiation, or fluid overload.

Graft failure. Failure of the graft (transplant) taking hold in the marrow is a potential complication. Graft failure may happen as a result of infection, recurrent disease, or if the stem cell count of the donated marrow was insufficient to cause engraftment.

Graft-versus-host disease. Graft-versus-host disease (GVHD) can be a serious and life-threatening complication of a bone marrow transplant. GVHD occurs when the donor's immune system reacts against the recipient's tissue. As opposed to an organ transplant where the patient's immune system will attempt to reject only the transplanted organ, in GVHD the new or transplanted immune system can attack the entire patient and all of his or her organs. This is because the new cells do not recognize the tissues and organs of the recipient's body as self. Over time and with the help of medicines to suppress the new immune system, it will begin to accept its new body and stop attacking it. The most common sites for GVHD are GI tract, liver, skin, and lungs.

Prognosis greatly depends on the following:

Type of transplant

Type and extent of the disease being treated

Disease response to treatment

Genetics

Your age and overall health

Read the rest here:
Bone Marrow Transplantation | Johns Hopkins Medicine

Bone Marrow Stem Cells Comments Off on Bone Marrow Transplantation | Johns Hopkins Medicine | December 20th, 2023

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)

See the article here:
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

Global News Feed Comments Off on Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering | December 20th, 2023

PALO ALTO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that a recent market research study among rheumatologists revealed a high degree of interest in Gloperba® as a liquid colchicine formulation designed for precision dosing.5 Specifically, clinicians using colchicine for prophylaxis of gout flares in adults indicated a strong likelihood to use Gloperba® instead of tablets/capsules in certain at-risk patient populations who have a clinical need for lowered precision dosing to mitigate the risk of colchicine toxicity. Notably, the American College of Rheumatology (ACR) guidelines also reflect this need.6 Scilex is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the dosing recommendations for these patient populations.

See more here:
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid...

Global News Feed Comments Off on Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid… | December 20th, 2023